2,4-Diaminoquinazolines as Dual Toll-like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus-Reference-Cited by-同舟云学术

2,4-Diaminoquinazolines as Dual Toll-like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus

Published:2018-07-02 Issue:14 Volume:61 Page:6236-6246
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Embrechts Werner¹^ORCID,Herschke Florence¹,Pauwels Frederik¹,Stoops Bart¹,Last Stefaan¹,Pieters Serge¹,Pande Vineet¹,Pille Geert¹,Amssoms Katie¹,Smyej Ilham¹,Dhuyvetter Deborah¹,Scholliers Annick¹,Mostmans Wendy¹,Van Dijck Kris¹,Van Schoubroeck Bertrand¹,Thone Tine¹,De Pooter Dorien¹,Fanning Gregory¹,Jonckers Tim H. M.¹,Horton Helen¹,Raboisson Pierre¹,McGowan David¹^ORCID

Affiliation:

1. Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00643

Reference23 articles.

1. Engineering immune therapy against hepatitis B virus

2. Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus

3. A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B

4. Benefits and risks of interferon therapy for hepatitis B

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploration of 1-(indolin-1-yl)-2-(thiazol-2-yl)ethan-1-one derivatives as novel anti-HBV agent with potential TLR7-agonistic effect;European Journal of Medicinal Chemistry;2024-09

2. Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology;ACS Medicinal Chemistry Letters;2024-01-09

3. Toll-Like Receptors 7/8: A Paradigm for the Manipulation of Immunologic Reactions for Immunotherapy;Viral Immunology;2023-11-01

4. Hepatitis B virus-induced hepatocellular carcinoma: a persistent global problem;Brazilian Journal of Microbiology;2023-04-14

5. Benzene fused pyrimidine-based derivatives and their biological properties;Fused Pyrimidine-Based Drug Discovery;2023